The therapeutic landscape for COVID-19 and post-COVID-19 medications from genetic profiling of the Vietnamese population and a predictive model of drug-drug interaction for comorbid COVID-19 patients

• Published in: Heliyon Vol. 10; no. 6; p. e27043
• Main Authors: Nguyen, Thien Khac, Vu, Giang Minh, Duong, Vinh Chi, Pham, Thang Luong, Nguyen, Nguyen Thanh, Tran, Trang Thi Ha, Tran, Mai Hoang, Nguyen, Duong Thuy, Vo, Nam S., Phung, Huong Thanh, Hoang, Tham Hong
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 30-03-2024; Elsevier
• Subjects: Chronic diseases; Correspondence; COVID-19 drugs; Drug interactions; Pharmacogenomics; Post-COVID-19 drugs; Vietnamese population; Post-COVID-19 drugs; Chronic diseases; COVID-19 drugs; Drug interactions; Pharmacogenomics; Vietnamese population
• DOI: 10.1016/j.heliyon.2024.e27043
• EISSN: 2405-8440

Despite the raised awareness of the role of pharmacogenomic (PGx) in personalized medicines for COVID-19, data for COVID-19 drugs is extremely scarce and not even a publication on this topic for post-COVID-19 medications to date. In the current study, we investigated the genetic variations associated with COVID-19 and post-COVID-19 therapies by using whole genome sequencing data of the 1000 Vietnamese Genomes Project (1KVG) in comparison with other populations retrieved from the 1000 Genomes Project Phase 3 (1KGP3) and the Genome Aggregation Database (gnomAD). Moreover, we also evaluated the risk of drug interactions in comorbid COVID-19 and post-COVID-19 patients based on pharmacogenomic profiles of drugs using a computational approach. For COVID-19 therapies, variants related to the response of two causal treatment agents (tolicizumab and ritonavir) and antithrombotic drugs are common in the Vietnamese cohort. Regarding post-COVID-19, drugs for mental manipulations possess the highest number of clinical annotated variants carried by Vietnamese individuals. Among the superpopulations, East Asian populations shared the most similar genetic structure with the Vietnamese population, whereas the African population showed the most difference. Comorbid patients are at an increased drug-drug interaction (DDI) risk when suffering from COVID-19 and after recovering as well due to a large number of potential DDIs which have been identified. Our results presented the population-specific understanding of the pharmacogenomic aspect of COVID-19 and post-COVID-19 therapy to optimize therapeutic outcomes and promote personalized medicine strategy. We also partly clarified the higher risk in COVID-19 patients with underlying conditions by assessing the potential drug interactions.